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Objective: Advances in radiation delivery, imaging tech-
niques, and chemotherapy have significantly improved 
treatment options for non-metastatic nasopharyngeal 
cancers (NPC). However, their impact on the practice in 
the United Kingdom (UK), where this tumour is rare, is 
unknown. This study examined the current attitudes of 
UK head and neck oncologists to the treatment of NPC.
Methods: UK head and neck oncologists representing 
19/23 cancer networks were sent an invitation email with 
a personalised link to a web-based survey designed to 
identify the influence of tumour and nodal staging on 
current NPC management practices.
Results: 26/42 (61%) of clinicians responded. Induction 
chemotherapy followed by concomitant chemoradi-
ation was the treatment of choice for Stage III (69%) 
and IVa/b (96%), with cisplatin and 5-fluorouracil 
combination being the most commonly used induction 
chemotherapy regimen (88%). 16 centres (61%) used 
a geometric approach, adding variable margins of 
0–10 mm to the gross tumour volume to define their 
therapeutic dose clinical target volume. 54% of respond-
ents used 3 radiotherapy (RT) prescription doses to 
treat NPC. Retropharyngeal nodal region irradiation 
policy was inconsistent, with nearly one-quarter treating 
the entire group to a radical dose.
Conclusion: Significant heterogeneity currently exists in 
the RT practice of NPC in the UK. A consensus regarding 
the optimal curative, function-sparing treatment para-
digm for NPC is necessary to ensure cancer survivors 
have satisfactory long-term health-related quality of 
life.
Advances in knowledge: This is the first study to high-
light the significant variation in RT practice of NPC in 
the UK.
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IntROduCtIOn
Primary intensity-modulated radiotherapy (IMRT), either 
alone or in combination with systemic chemotherapy, 
forms the mainstay of curative treatment for nasopharyn-
geal cancers (NPC), achieving 2-year loco-regional control 
and overall survival rates of 86% in the UK.1 The addi-
tion of concomitant chemotherapy to radiotherapy (RT) 
confers an absolute 10 year survival advantage of 9.9% 
over RT alone in locally advanced Stage III/IVb NPC,2 
and is the recommended standard of care in the recently 
published UK multidisciplinary national guidelines.3 The 
role of induction chemotherapy (IC) or adjuvant chemo-
therapy (AC), in addition to concomitant chemoradiation 
(CRT), to improve survival outcomes remains contentious, 
with conflicting results from several meta-analyses.2,4–8 
Despite such uncertainty, current international guidance 
supports the use of IC or AC in locally advanced tumours, 
provided the delivery of definitive RT is not compromised.9 
At present, it is unclear whether either of these strategies is 
integrated into routine UK practice for NPC.
Conventional RT target volumes for NPC are large in 
the UK, in which the entire nasopharyngeal compart-
ment, retropharyngeal lymph nodes (RPN) and involved 
nodal levels are treated to a radical dose of 65 Gy while 
uninvolved bilateral Ib–V neck nodes are irradiated to a 
prophylactic RT dose of 54 Gy, delivered over 30 fractions. 
However, these therapeutic approaches adversely impact 
on the long-term functional quality of life in cancer survi-
vors due to treatment-related toxicities, especially xero-
stomia, dysphagia and damage to the temporal lobe.10,11 
NPC is rare in the UK,3 and consequently there is a lack 
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Table 1. Centre location, number of radical treatments of NPC 
per year, and staging imaging used for NPC
Number (percentages)
Region
  England 22 (84%)
  Wales 2 (8%)
  Scotland 1 (4%)
  Northern Ireland 1 (4%)
NPC treated radically each year
  0–5 19 (73%)
  6–10 7 (27%)
Staging imaging modality 
  MRI 2 (8%)
  PET-CT 1 (4%)
  MRI + PET-CT 4 (16%)
  MRI + CT 10 (38%)
  MRI + CT + PET-CT 9 (34%)
PET-CT, positron emission tomography; NPC, nasopharyngeal 
cancers.
Figure 1. UK centres’ treatment strategy for NPC by stage (n 
= 26).
of motivation to refine such established curative, but consid-
erably morbid management strategies. On the other hand, a 
number of currently accruing toxicity-mitigating trials in oro- 
and hypo-pharyngeal cancers12–14 have the potential to shape 
future organ-sparing protocols in these tumours. Such a notable 
disparity in the national research portfolio could potentially 
dichotomise long-term functional outcomes for pharyngeal 
cancer patients, and there is, therefore, an urgent unmet need to 
establish a consensus on safe, less morbid RT strategies for NPC 
in the UK. Potentially favourable evidence-based RT protocols15 
have been implemented in Asia, where this tumour is endemic. 
Geographical variations in prognostic epidemiological patterns 
of NPC,16 such as the significant prevalence of Epstein-Barr 
virus–associated good prognosis non-keratinizing, undifferenti-
ated carcinoma in the Far East compared to the Western World, 
appear to limit the incorporation of similar treatment options 
into standard treatment protocols in non-endemic regions such 
as North America and UK.
This study aims to understand the variation in current NPC 
management amongst the different UK centres.
MethOdS And MAteRIAlS
We performed an observational, web-based survey, which 
comprised 19 questions exploring local treatment protocols 
for the management of non-metastatic NPC, with particular 
emphasis on radiotherapy practice for different tumour stages. 
It was developed using Bristol Online Survey—a survey tool 
available on  www. onlinesurvays. ac. in.  The final version of 
the survey (Supplementary Material 1,  Supplementary mate-
rial available online) and accompanying protocol were scien-
tifically reviewed and approved as a service evaluation by the 
Royal Marsden NHS Foundation Trust Clinical Committee for 
Research (SE531).
The personalised link to the survey was distributed via an invi-
tation email to 42 UK head and neck (HN) oncologists repre-
senting 19 of the 23 cancer research networks who had expressed 
an interest in either ARTDECO (ISRCTN 01483375)17 or DARS 
(ISRCTN 25458988)12-two Cancer Research UK (CRUK)-
funded multicentre HN randomised controlled trials. In order 
to maintain anonymity of responding clinicians, no identifiable 
information was captured in the survey responses. The survey 
was available for completion for a period of 4 weeks in June and 
July 2016.
Statistical analysis
Descriptive statistics were used. Results were collated and 
presented as percentages to determine the influence of tumour 
and nodal staging on management practices.
ReSultS
Participants
Clinicians from 26 centres (61%) completed the survey. Of those 
who responded, 92% (n = 24/26) completed the questionnaire 
fully. Centre location, referral numbers and imaging modalities 
used to stage NPC are included in Table 1.
Treatment strategy as per stage
Disease was staged according to the 2010 American Joint 
Committee on Cancer (AJCC) criteria. 20/26 (77%) of centres 
stated that they offered primary RT alone for Stage I NPC (20/26; 
77%), while patients with Stage II NPC were more likely to be 
treated with concurrent CRT (16/26; 61%). IC followed by CRT 
was the treatment of choice for Stage III (18/26; 69%) and Stage 
IVa/b NPC (25/26; 96%) (Figure 1).
Chemotherapy practice
Only one centre does not subscribe to the use of IC or AC, 
offering primary RT for Stage I NPC and concurrent CRT for 
Stage II–IVa/b NPC. With regards to IC, 22/25 centres (88%) 
prescribed cisplatin and 5-fluorouracil (CF), with 10 and 12 
of these centres offering 2 and 3 cycles of CF respectively. The 
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Figure 2. Cumulative prophylactic dose nodal-CTV irradiation 
policy in node-negative NPC (n = 24). CTV, clinical target vol-
ume; NPC, nasopharyngeal cancers.
Figure 3. Cumulative prophylactic dose nodal-CTV irradiation 
policy in node-positive NPC (n = 24). 
remaining 3 centres administered 2 cycles of induction cisplatin, 
5-FU and docetaxel (TPF).
Two centres offered 3 cycles of adjuvant CF following concurrent 
CRT for Stage III NPC, with one of these centres also routinely 
prescribing AC for Stage II NPC.
Radiotherapy practice
Rotational arc-based IMRT was widely used (20/26; 77%) 
to deliver radical RT for NPC, with the remaining centres 
using fixed-field IMRT. No centre practised conventional 3-D 
conformal RT. Half of UK centres completing the survey used 
MRI in radiotherapy planning position co-registered with the 
planning CT scan to aid delineation of RT target volumes and 
organs at risk.
Dose prescription
A large proportion of centres (14/26; 54%) employed 3 dose-vol-
umes: radical dose of 70 Gy (or equivalent), intermediate dose 
60 Gy and elective dose of 54–56 Gy for Stage III/IVb NPC. 11 
centres (42%) used 2 dose-volumes: radical dose of 65 Gy, and 
elective dose of 54 Gy, delivered over 30 fractions. One centre 
stated its standard practice was to use 4 dose-levels—prescribing 
70 Gy to the primary tumour, 66 Gy to the remaining NPC and 
any involved lymph node (LN) regions, 60 Gy and 54 Gy to 
“high risk” and “low risk” LN respectively; all delivered over 33 
fractions.
Therapeutic dose clinical target volume (CTV) 
selection
The majority of responding centres (16/26; 61%) defined 
their therapeutic CTV using a geometric approach, while the 
remaining 10 centres adopted an anatomical approach and irra-
diated the entire nasopharynx to a radical RT dose. Amongst 
those centres that employed a geometric approach, seven added 
a margin of 10 mm to both primary and nodal gross tumour 
volumes (GTVs) to create the CTV. Corresponding primary and 
nodal GTV–CTV margins for the other centres were as follows: 
5 mm and 10 mm (4/16), 6 mm (1/16), 5 mm (1/16), 0 mm and 
10 mm (1/16), 10 mm and entire nodal level (1/16), and variable 
margins and entire nodal level (1/16).
Prophylactic dose nodal-CTV selection
To standardise survey responses, level II was the chosen site 
of nodal disease that would be irradiated to a radical dose in 
node-positive NPC.
For T1/2 node-negative NPC, most centres irradiated level IVa 
electively (IVa - 21/25, 84%) in addition to levels II, III and 
Va; however there was uncertainty about including levels IVb 
(14/25, 56%), and Vc (supraclavicular fossa, SCF; 10/25, 40%) 
respectively. One centre stipulated that it did not prophylacti-
cally irradiate any nodes in this stage, reserving it for T3/4 node- 
negative tumours only. In comparison, level Ib was treated more 
frequently in T3/4 node-negative NPC (Figure  2). RT nodal 
coverage was much more extensive for node-positive disease, 
with most centres treating the entire neck and nearly all included 
level Ib on the node-positive side of the neck (Figure 3).
RPN volume definition and dose prescription
18 centres (69%) included both the medial and lateral groups of 
RPN in the RT target volumes, and seven centres (23%) treated 
this group along its entire length (upper edge of body of C1/
hard palate to cranial edge of hyoid bone) to a dose equivalent to 
70 Gy (radical dose).
dISCuSSIOn
The results from this survey illustrate significant variability in 
the management of NPC in the UK. These include differences 
in radical RT target volumes, selection of prophylactic dose 
nodal-CTV and RPN volumes, and the role of systemic chemo-
therapy in different stages of NPC.
The routine integration of MRI in the RT planning process has 
improved the accuracy of primary tumour evaluation with its 
excellent soft tissue discrimination.18 This has overcome the 
widely acknowledged shortcomings associated with CT-based 
GTV delineation19–21 that justified the historical inclusion of 
the entire nasopharyngeal compartment in the therapeutic radi-
ation dose. A direct consequence of advances in both imaging 
and RT delivery has been the delineation of smaller therapeutic 
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Figure 4. Patterns of regional lymph node metastasis from NPC, *Incidence of nodal metastasis in Va and Vb were 21.5 and 15.6% 
respectively in Wang et al. NPC, nasopharyngeal cancers.
dose CTV in NPC. Such target volumes, which are generated by 
adding variable margins to GTV, minimise the risk of long-term 
treatment-related toxicities without any detrimental impact on 
survival outcomes. To avoid the risk of geographical misses in 
the era of highly conformal IMRT, however, we feel that rigid 
co-registration of MRI in the RT planning position with a simi-
larly acquired planning CT is an essential pre-requisite for reli-
able tumour delineation.22 Resource limitations mean that this 
facility is not readily available in all UK radiotherapy centres.
Strong evidence from MRI-based imaging studies in NPC-en-
demic regions have refined current understanding of distribution 
of nodal metastasis (Figure 4), concluding that the disease spread 
is orderly, with a preferential predilection to spread to the upper 
cervical nodes (levels II, III, and Va), and that the likelihood of 
“skip” metastasis is rare.19,23–25 Such studies support the intro-
duction of a personalised, selective nodal irradiation strategy, 
which is likely to be less toxic. Li et al successfully explored this 
proof of principle in a Phase III, non-inferiority, randomised 
controlled trial comparing prophylactic upper neck radiation 
alone against whole neck radiation in node-negative NPC.26 Their 
study, in which nearly two-thirds of patients had T3/4 tumours, 
demonstrated equivalent 3 year survival [89.5 vs 87.4%, hazard 
ratio (HR) 0.86, 95% confidence Interval (CI) (0.41–1.82), p 
= 0.70] and relapse–free rates [89.8 vs 89.3%, HR 0.91, 95% 
CI (0.42–2.00), p = 0.82] in the two arms, thereby confirming 
that prophylactic irradiation of upper nodal levels was adequate 
in node-negative non-keratinizing, undifferentiated NPC. 
Sparing the lower neck, and level Ib is likely to have a favourable 
influence on patients’ health-related quality of life (HR-QoL), 
by reducing the risk of long-term thyroid dysfunction, carotid 
artery atherosclerosis, apical lung fibrosis, skin fibrosis and 
xerostomia.
RPN metastasis in NPC is common, occurring in nearly 
three-quarters of newly diagnosed cases. It is also associated 
with worsened survival outcomes,27 leading to empirical irradi-
ation of this nodal group in NPC, regardless of stage at presen-
tation. Evidence-based delineation of this LN group, along with 
selecting the most appropriate RT dose are crucial, however, in 
order to reduce long-term treatment-related morbidity. In this 
regard, it is noteworthy that involvement of the medial group of 
RPN is extremely rare (<1%) in NPC, and always associated with 
other sites of nodal metastasis, as highlighted by a large prospec-
tive MRI-based study.28 Further corroboration is delivered by the 
recent publication of the updated international consensus nodal 
delineation guidelines, in which the medial RPN is excluded 
from level VIIa.29 Sparing the medial RPN reduces the RT dose 
to the pharyngeal constrictor muscles, a key swallowing struc-
ture implicated in post-RT dysphagia, and may minimise long-
term swallowing dysfunction.30 Furthermore, successive studies 
have failed to demonstrate significant differences in outcomes 
between tumours involving RPN and those with neck nodes 
< 6 cm above SCF—both of which are staged as N1 in the current 
NPC staging system.31,32 The rationale, therefore, to irradiate 
RPN to a radical dose while including levels II–III in the elective 
dose, when these nodal regions are free of macroscopic disease, 
is flawed.
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Table 2. UK centres’ prophylactic dose nodal-CTV selection 
for node-negative NPC
Centre
nos Ib II III Va Vb IVa IVb Vc
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Upper Neck (UN) Nodal Level (NL)       
NLs included in addition to UN       
“Under-selection” of UN NL       
NL not included in T1/2 N0 disease       
NL not included in target volumes       
CTV, clinical target volume; NPC, nasopharyngeal cancers.
The rationale for adding IC to CRT in NPC is based mainly on the 
premise that it reduces rates of distant metastasis through early 
elimination of micro-metastatic disease, tumour shrinkage can 
occur before RT, and treatment compliance is better compared 
to AC. Such anticipated benefits, however, have failed to translate 
into clear survival advantages over CRT alone in the published 
meta-analyses, and consequently IC is not recognised globally as 
the therapeutic option of choice for Stage III–IVb NPC. Nonethe-
less, a recently reported comprehensive individual patient data 
network meta-analysis (NMA) by Blanchard et al showed that CRT 
was non-significantly inferior to IC followed by CRT for PFS, loco- 
regional and distant control,33 which suggests that there 
may be a beneficial role for IC in carefully selected locally 
advanced NPC. NPC patients in the UK are more likely to 
present with a primary tumour volume >25 cm,31 which has 
been linked with worsened survival and distant recurrence 
rates.34 Therefore, it is plausible to postulate that patients with 
predominantly bulky disease in the UK benefit from IC, as 
demonstrated in our Phase II study.1 Furthermore, a recently 
published Phase III randomised study by Sun et al reported a 
significantly improved 3 year failure-free survival [80 vs 72%; 
HR 0.68, 95 % CI (0.48–0.97); p = 0.034], overall survival [92 
vs 86%; HR 0.59, 95% CI (0.36–0.95); p = 0.029], and distant 
failure-free survival [90 vs 83%; HR 0.59, 95% CI (0.37–0.96); 
p = 0.031] rates when dose-reduced induction TPF was added 
to CRT, compared to concomitant CRT alone.35 With regards to 
AC, again there are no proven survival advantages over CRT in 
the published literature. The NMA by Blanchard et al did show 
that it achieved the highest survival benefit amongst the different 
regimens for NPC and is, therefore, an acceptable regimen.
How much evidence-based is radical NPC treatment in the UK? 
Nearly 40% (10/26) of respondents in this survey irradiated 
the entire compartment to a radical dose, though half of these 
centres (5/10) did not have a planning MRI at their disposal, 
which is likely to be a contributory factor for not reducing target 
volumes. The remaining five centres routinely had a planning 
MRI at their disposal; yet they selected an anatomical approach 
to define their radical dose. We would consider their approach as 
very conservative, and not in keeping with international practice, 
where the GTV is expanded by upto 5 mm to generate the high-
dose CTV.36–38 Interestingly, 8 of the 16 centres that employed 
a geometric approach to select their therapeutic CTV did not 
utilise a RT planning MRI. Instead, they relied on the diagnostic 
MRI for the purpose of tumour delineation. This methodology is 
associated with considerable inter- and intra-observer variation, 
and in our opinion not reliable for accurate target volume delin-
eation, though there may be a role for using deformable registra-
tion to integrate the diagnostic MRI and minimise contouring 
errors in such situations.39
This survey additionally demonstrated that prophylactic nodal 
(including RPN) CTV selection in the UK was extensive, incon-
sistent and not evidence-based in node-negative NPC, with 
many centres reluctant to exclude the lower neck, while some 
erroneously believed that a higher T-stage was associated with 
a higher risk of microscopic disease in levels Ib and the lower 
neck (Table  2). Volume selection amongst responding centres 
in node-positive disease was largely non-selective (Table  3), 
reflecting traditional UK perception that NPC is a tumour with 
an aggressive propensity for loco-regional spread and, there-
fore, justifying the negative culture of a blanket nodal RT target 
volume policy.3 Medial RPN is frequently included in target 
volumes, with almost a quarter irradiating the entire RPN to 
a radical dose. Careful re-evaluation of such assumptions are 
necessary, particularly in an era where there is an increasing drive 
to develop a personalised, toxicity-sparing approach to manage 
tumours. One could argue that the reported positive outcomes 
from NPC-endemic regions, where good-prognosis, virus-as-
sociated non-keratinising, undifferentiated (Type III) NPC 
predominates, cannot be readily extrapolated to the non-viral, 
keratinising (Type I) and non-keratinising well differentiated 
(Type II) NPC commonly diagnosed in the Western world.16 
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However, this distinction in the global distribution of prognostic 
NPC histological sub-types is not absolute. Recent literature 
suggests that Type III NPC constituted between 55–65% of newly 
diagnosed NPC in the UK, and upto 30% of such patients might 
have no nodal disease at presentation.1,40 We feel that a more 
pragmatic approach, therefore, would be to adopt the favour-
able selective nodal irradiation policy in Type III, node-negative 
tumours, while reserving the standard protocol for node-positive 
disease. In fact, evidence is also gradually emerging regarding 
the feasibility of irradiating reduced nodal volumes in node-pos-
itive NPC,41,42 but this approach still requires prospective valida-
tion prior to adopting into clinical practice.
The use of IC in the radical treatment of NPC is a popular strategy 
in the UK. Long-term toxicity and survival outcomes from the 
study by Sun et al, together with results from additional IC trials16 
should clarify, in the future, the definitive role of IC in the manage-
ment of NPC. Until these results are available, it is likely that IC 
will continue to form a significant part of the treatment strategy in 
the UK for locally advanced NPC. In this context, we would like to 
point out that the 2 IC regimens used in the published positive IC 
trials in NPC were 3 and 2 cycles of TPF and cisplatin-docetaxel, 
respectively. Currently, the evidence is lacking regarding the use 
of 2–3 cycles of induction PF in NPC, as prescribed by a majority 
of responding UK centres. The issue of whether to use pre- or 
post- IC tumour volumes for RT delineation was investigated in a 
randomised study which showed that the use of post-IC volumes 
were associated with a significant improvement in HR-QoL with 
no detrimental impact on survival outcome.43 The use of AC is rare 
in the UK, reflecting concerns about toxicity and compliance with 
this approach.
There are certain limitations to this survey. The response rate was 
61% and it is probable that non-responding centres may have a 
different opinion on the management strategy, resulting in selec-
tion bias. The response rate is, however, comparable to similar 
surveys undertaken for other HNC and tumour sites in the UK.44,45 
Furthermore, only the local principal investigator (PI) from each 
centre taking part in either ARTDECO or DARS was invited to 
take part in the survey, and it can be argued that their treatment 
paradigm may not necessarily be representative of other HN oncol-
ogists at their respective centre. However, we believe it is routine 
practice for UK cancer centres to have local chemotherapy and RT 
guidelines for various tumour sites, and there is a high likelihood 
that oncologists in one centre will uniformly adhere to those guide-
lines. Therefore, it is reasonable to assume that the practice policy 
of each PI is reflective of other HN oncologists at their centre. RT 
contouring variation between HN oncologists in a centre may 
occur, but significant differences are more likely with complex clin-
ical cases.46 This was not the aim of this survey, which was under-
taken to understand the variability in standard practice patterns for 
different stages of non-metastatic NPC. We also did not explicitly 
explore the influence of the T-stage on management practice for 
node-positive NPC. Finally, the survey did not specifically enquire 
whether centres stratified their practice as per the histological 
sub-type. However, none of the responding centres highlighted this 
in the several free-text opportunities provided within the survey, 
and it can, therefore, be assumed with a degree of certainty that 
centre policy was independent of histology.
COnCluSIOnS
The contemporary management for non-metastatic NPC 
represents a significant clinical enigma, requiring a balance 
between curative and function-preserving strategies. This 
survey demonstrates that significant challenges exist in the UK 
to achieve this, as highlighted by the large variation in target 
volume selection amongst different centres. Optimal application 
of available imaging techniques to better define CTV, selective 
nodal irradiation in node-negative tumours, prospective peer 
review of target volumes,47 and evidence-based practice for the 
use of chemotherapy across all NPC stages should be consid-
ered to improve current practice (Table  4). Developing a RT 
consensus for NPC in the UK is essential, and in this regard, we 
welcome the recent endeavour of our colleagues to initiate this,48 
and expect that this survey will provide definitive information to 
finalise a national consensus.
Table 3. UK centres’ prophylactic dose nodal-CTV selection 
for node-positive NPC
Centre nos Ib II III Vab IVa IVb Vc
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
NL included on both sides of neck      
Additional NL included in node+      
CTV, clinical target volume; NPC, nasopharyngeal cancers.
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